ABOS
Price
$2.06
Change
+$0.03 (+1.48%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
146.8M
4 days until earnings call
Intraday BUY SELL Signals
SKYE
Price
$1.62
Change
-$0.01 (-0.61%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
7.22M
18 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABOS vs SKYE

ABOS vs SKYE Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABOS vs. SKYE commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a StrongBuy and SKYE is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ABOS with price predictions
Oct 21, 2026

ABOS's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for ABOS turned positive on October 21, 2026. Looking at past instances where ABOS's MACD turned positive, the stock continued to rise in 40 of 45 cases over the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ABOS's RSI Oscillator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 58 cases where ABOS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

Following a +14.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABOS advanced for three days, in 207 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

ABOS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABOS as a result. In 78 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

ABOS moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ABOS crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for ABOS entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.564) is normal, around the industry mean (2.988). P/E Ratio (-1.238) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. ABOS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABOS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for SKYE with price predictions
Oct 21, 2026

SKYE in upward trend: price may jump up because it broke its lower Bollinger Band on October 13, 2026

SKYE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 42 of 49 cases where SKYE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 68 cases where SKYE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Moving Average Convergence Divergence (MACD) for SKYE just turned positive on September 21, 2026. Looking at past instances where SKYE's MACD turned positive, the stock continued to rise in 31 of 39 cases over the following month. The odds of a continued upward trend are 79%.

Following a +6.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where SKYE advanced for three days, in 203 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SKYE as a result. In 84 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SKYE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for SKYE entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-14.512) is normal, around the industry mean (2.988). P/E Ratio (-0.159) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.130) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. SKYE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SKYE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
SKYE: Fundamental Ratings
SKYE
OUTLOOK RATING
1..100
29
VALUATION
overvalued / fair valued / undervalued
1..100
10
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
91
P/E GROWTH RATING
1..100
7
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABOSSKYE
RSI
ODDS (%)
Bullish Trend 2 days ago
87%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 7 days ago
83%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 8 days ago
87%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ABOS: $2.03 vs. SKYE: $1.63)
Brand notoriety: ABOS and SKYE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABOS: 67% vs. SKYE: 13%
Market capitalization -- ABOS: $148.97M vs. SKYE: $7.17M
ABOS [@Biotechnology] is valued at $148.97M. SKYE’s [@Biotechnology] market capitalization is $7.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABOS’s FA Score shows that 1 FA rating(s) are green while SKYE’s FA Score has 2 green FA rating(s).

  • ABOS’s FA Score: 1 green, 4 red.
  • SKYE’s FA Score: 2 green, 3 red.
According to our system of comparison, SKYE is a better buy in the long-term than ABOS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABOS’s TA Score shows that 5 TA indicator(s) are bullish while SKYE’s TA Score has 4 bullish TA indicator(s).

  • ABOS’s TA Score: 5 bullish, 5 bearish.
  • SKYE’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, SKYE is a better buy in the short-term than ABOS.

Price Growth

ABOS (@Biotechnology) experienced а +16.33% price change this week, while SKYE (@Biotechnology) price change was +3.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

ABOS is expected to report earnings on Oct 26, 2026.

SKYE is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ABOS
Daily Signal:
Gain/Loss:
SKYE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ABOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with CCXI. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then CCXI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
+0.74%
CCXI - ABOS
48%
Loosely correlated
-0.05%
EDIT - ABOS
46%
Loosely correlated
-2.71%
SANA - ABOS
43%
Loosely correlated
-0.42%
RCKT - ABOS
42%
Loosely correlated
-5.98%
NKTX - ABOS
41%
Loosely correlated
+0.57%
More

SKYE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SKYE has been loosely correlated with VKTX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if SKYE jumps, then VKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SKYE
1D Price
Change %
SKYE100%
+0.62%
VKTX - SKYE
34%
Loosely correlated
-1.24%
ABOS - SKYE
30%
Poorly correlated
+0.74%
RCKT - SKYE
30%
Poorly correlated
-5.98%
IPSC - SKYE
29%
Poorly correlated
-1.83%
NRIX - SKYE
28%
Poorly correlated
-0.31%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SWBI15.100.32
+2.17%
Smith & Wesson Brands
NI42.990.23
+0.54%
NiSource
MCHB14.630.03
+0.21%
Mechanics Bancorp
GRO2.05N/A
N/A
Brazil Potash Corp
PLAG0.46-0.03
-6.17%
Planet Green Holdings Corp